Lexicon Pharmaceuticals | LXRX - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Abbott USD 2.25B 73M 2025-12
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Illumina USD 256M 6M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
J&J USD 5.59B 1.81B 2025-12
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
MannKind USD -69.24M 28.19M 2025-12
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Novartis USD 4.06B 437M 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Thermo Fisher Scientific USD 2.3B 226M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12